The Department of Health and Social Care has extended a strict one-month supply limit on ramipril 1.25 mg capsules through October 30, according to recent updates from health authorities. The ongoing restriction has intensified calls from pharmacy leaders for broader substitution powers to ease pressure on patients and general practice clinics.
Ramipril Supply Limit and Serious Shortage Protocol Background
According to the Department of Health and Social Care, the serious shortage protocol for ramipril 1.25 mg capsules mandates that pharmacies restrict dispensing to a one-month quantity per prescription, regardless of the duration ordered by the prescriber. The measure applies to both NHS and private prescriptions across all four UK nations. Government guidance specifies that patients do not pay a prescription charge when receiving a reduced quantity under this protocol.
Ramipril is an angiotensin-converting enzyme inhibitor utilized by approximately 6 million people in the UK. Data indicates that around 14 million adults live with high blood pressure, making ramipril the most commonly prescribed antihypertensive and a top-10 medication overall. Prescribers frequently favor the drug because its long half-life permits once-daily dosing.
Pharmacist Calls for Professional Substitution Powers
National Pharmacy Association chair Olivier Picard described the extended shortage as concerning for millions of patients who rely on the medication. According to Picard, while alternative medicines exist, the government must manage supplies carefully to match subsequent demand.
Current serious shortage protocol regulations prevent pharmacists from using their professional judgment to substitute an alternative product without contacting the original prescriber or directing the patient back to their GP. Picard urged the government to grant pharmacists appropriate substitution authority so patients can avoid repeat GP visits simply to find an alternative.
While ramipril 1.25 mg and 2.5 mg tablets, as well as an oral solution, remain available, the Department of Health and Social Care warned that supply chains could not support increased demand if all capsule users switched to those alternative formulations simultaneously.
Wider Medicine Shortages and Industry Response
Picard noted that ramipril represents just one of numerous supply disruptions affecting everyday medicines in recent years, with some sector professionals describing current shortages as the worst they have ever experienced. Fragility in global supply chains, compounded by international instability, continues to drive these inventory pressures.
Following recent Cabinet appointments, Picard called for the establishment of a dedicated taskforce to address what he characterized as a chronic problem affecting community pharmacies across the country.
Related reading